Immunovant, Inc. (NASDAQ:IMVT), a biopharmaceutical company specializing in biological products currently valued at $3.4 billion, has registered shares for resale by certain selling stockholders ...

Wells Fargo analyst Derek Archila lowered the firm’s price target on Immunovant (IMVT) to $45 from $47 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid ...

Immunovant anticipates receiving aggregate gross proceeds of approximately $450 million from the PIPE. The PIPE is expected to close on or about January 15, 2025, subject to the satisfaction of ...

In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging” year ...

It’s show-me time for batoclimab, the FcRn-targeting antibody treatment from Immunovant and Roivant Sciences. A consequential Phase 3 study readout is coming before the end of the first quarter.

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report)’s share price fell 5% on Thursday following a weaker than expected earnings announcement.The company traded as low as $21.71 and last traded at ...

BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $45 from $48 and keeps a Buy rating on the shares after the company agreed to sell 22.5M shares of common ...

Immunovant, Inc. reported significant progress related to its lead asset IMVT-1402, having secured six Investigational New Drug applications and currently enrolling participants in pivotal studies ...

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today ...